SCHEMBL17134650

SCHEMBL17134650

COc1ccc(Nc2c(C(=O)N3CCC(c4ccc(F)cc4)CC3)cnc(S(N)(=O)=O)c2Cl)c(Cl)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRPC6 Q9Y210 6/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ LMNA P02545 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ HSD11B1 P28845 1/20 0.41
▸ NPC1 O15118 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ PARP10 Q53GL7 2/20 0.40
▸ PRSS12 P56730 2/20 0.39
▸ CSF1R P07333 1/20 0.39
▸ CPS1 P31327 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.38
▸ CYP2D6 P10635 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ FASN P49327 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17184254 0.94 TRPC6 (0.45) TRPC6SMN1; SMN2ALDH1A1LMNAHTT
SCHEMBL17184257 0.94 TRPC6 (0.45) TRPC6SMN1; SMN2ALDH1A1LMNAHTT
SCHEMBL17135205 0.93 TRPC6 (0.44) TRPC6SMN1; SMN2ALDH1A1LMNAHTT
SCHEMBL17184230 0.89 TRPC6 (0.42) TRPC6SMN1; SMN2ALDH1A1LMNAHTT
SCHEMBL17135093 0.89 SMN1; SMN2 (0.46) TRPC6SMN1; SMN2ALDH1A1LMNAHTT
SCHEMBL17134775 0.88 TRPC6 (0.45) TRPC6SMN1; SMN2ALDH1A1LMNAHTT
SCHEMBL17134994 0.88 TRPC6 (0.43) TRPC6SMN1; SMN2ALDH1A1LMNAHTT
SCHEMBL17134832 0.86 FASN (0.43) TRPC6SMN1; SMN2ALDH1A1PARP10PRSS12
SCHEMBL17135140 0.86 KCNH2 (0.41) TRPC6SMN1; SMN2ALDH1A1HSD11B1PARP10
SCHEMBL17135024 0.86 FASN (0.39) TRPC6ALDH1A1HSD11B1PARP10PRSS12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2927214-B1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND KYOWA HAKKO KIRIN CO LTD (JP) 2018-03-21 — — EP disclosed
US-9701689-B2 Substituted pyridines and pyridazines as CCR10 receptor inhibitors KYOWA HAKKO KIRIN CO., LTD. (JP) 2017-07-11 — — US disclosed
US-20150299214-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND KYOWA HAKKO KIRIN CO., LTD. (JP) 2015-10-22 — — US disclosed
EP-2927214-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND Kyowa Hakko Kirin Co., Ltd. (JP) 2015-10-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150299214-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND ARG1, H1-0, TYR TRPC6 1469/4885SMN1; SMN2 2509/4885ALDH1A1 1322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback